These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19088467

  • 1. Route of epoetin administration influences hemoglobin variability in hemodialysis patients.
    Patel T, Hirter A, Kaufman J, Keithi-Reddy SR, Reda D, Singh A.
    Am J Nephrol; 2009; 29(6):532-7. PubMed ID: 19088467
    [Abstract] [Full Text] [Related]

  • 2. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG, Wright EC, Narva AS, Noguchi CT, Eggers PW.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1822-30. PubMed ID: 26358266
    [Abstract] [Full Text] [Related]

  • 3. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
    Thadhani R, Guilatco R, Hymes J, Maddux FW, Ahuja A.
    Am J Nephrol; 2018 Oct 07; 48(3):214-224. PubMed ID: 30196301
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, End-Stage Renal Disease Core Indicators Work Group.
    Am J Kidney Dis; 2001 May 07; 37(5):E36. PubMed ID: 11325701
    [Abstract] [Full Text] [Related]

  • 5. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients.
    Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, Sanadgol H, Amini S, Shahvaroughi Farahani A.
    Am J Nephrol; 2018 May 07; 48(4):251-259. PubMed ID: 30253403
    [Abstract] [Full Text] [Related]

  • 6. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P, Ketteler M, Hennemann H, Dömling R.
    Clin Nephrol; 2008 Mar 07; 69(3):185-92. PubMed ID: 18397717
    [Abstract] [Full Text] [Related]

  • 7. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar 07; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA.
    N Engl J Med; 1998 Aug 27; 339(9):578-83. PubMed ID: 9718376
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM, Collins DM, Penner SB.
    J Clin Pharmacol; 2005 Aug 27; 45(8):895-900. PubMed ID: 16027399
    [Abstract] [Full Text] [Related]

  • 12. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 27; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

  • 13. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr 27; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of once-weekly epoetin alfa.
    Barre P, Reichel H, Suranyi MG, Barth C.
    Clin Nephrol; 2004 Dec 27; 62(6):440-8. PubMed ID: 15630903
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul 27; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.